HYPERA S.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 27.15 BRL | -5.66% |
|
-4.40% | -24.06% |
| Mar. 14 | Transcript : Hypera S.A., Q4 2023 Earnings Call, Mar 14, 2024 | |
| Mar. 14 | Hypera S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
| Sales 2024 * | 8.66B 1.68B | Sales 2025 * | 9.57B 1.86B | Capitalization | 17.18B 3.33B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.86B 361M | Net income 2025 * | 2.21B 428M | EV / Sales 2024 * | 2.84 x |
| Net Debt 2024 * | 7.44B 1.44B | Net Debt 2025 * | 6.54B 1.27B | EV / Sales 2025 * | 2.48 x |
| P/E ratio 2024 * |
9.2
x | P/E ratio 2025 * |
8.18
x | Employees | 10,301 |
| Yield 2024 * |
4.62% | Yield 2025 * |
5.37% | Free-Float | 58.5% |
More Fundamentals
* Assessed data
More news
Latest transcript on Hypera S.A.
| 1 day | -5.66% | ||
| 1 week | -4.40% | ||
| Current month | -17.55% | ||
| 1 month | -20.38% | ||
| 3 months | -14.06% | ||
| 6 months | -18.20% | ||
| Current year | -24.06% |
1 week
27.11
29.25
1 month
27.1133.66
Current year
27.1136.34
1 year
27.1146.84
3 years
26.2551.11
5 years
26.0751.11
10 years
14.0651.11
| Managers | Title | Age | Since |
|---|---|---|---|
| Director of Finance/CFO | 36 | 22-02-23 | |
| Compliance Officer | 40 | 07-12-31 | |
| Investor Relations Contact | 42 | 15-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 74 | - | |
| Director/Board Member | 58 | - | |
| Director/Board Member | 49 | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.79% | 2 M€ | -14.14% | ||
| 0.92% | 21 M€ | -12.65% | - | |
| 0.86% | 15 M€ | -3.58% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 27.15 | -5.66% | 4,895,800 |
| 24-04-24 | 28.78 | -1.07% | 2,948,000 |
| 24-04-23 | 29.09 | +0.31% | 3,109,900 |
| 24-04-22 | 29 | +2.29% | 4,235,000 |
| 24-04-19 | 28.35 | -0.18% | 4,854,100 |
Delayed Quote Sao Paulo, April 25, 2024 at 04:07 pm EDT
More quotes
Hypera (formerly Hypermarcas) is the Brazilian leader in the manufacture and marketing of pharmaceutical products. The products are sold primarily under the Addera D3, Adocyl, AdultMax, Alivium, Apracur, Atroveran, Benegrip, Bigfral, Biotonico Fontoura, Coristina, Cremer, Doril, Engov, Epocler, Lisador and Neo Quimica. The activity is organized around 3 families of products :
- OTC medicines;
- prescription medicines;
- branded generic medicines.
Sector
Pharmaceuticals
Calendar
2024-04-25
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
27.15
BRL
Average target price
41.53
BRL
Spread / Average Target
+52.98%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -24.06% | 3.33B | |
| +24.91% | 556B | |
| -6.33% | 354B | |
| +19.90% | 331B | |
| +7.95% | 296B | |
| +13.87% | 233B | |
| +5.84% | 201B | |
| -10.10% | 193B | |
| -12.26% | 143B | |
| -6.47% | 144B |
- Stock Market
- Equities
- HYPE3 Stock
